AstraZeneca plc AZN and partner Merck announced this week that the European Commission has approved the two companies’ PARP inhibitor, Lynparza (olaparib). Lynparza has been approved as a monotherapy, for a new patient population suffering germline BRCA-mutated HER2-negative locally-advanced/metastatic breast cancer, who were previously treated with chemotherapy. Lynparza is the first approved PARP-inhibitor for treating … Continue reading “AstraZeneca and Merck’s Breast Cancer Drug Lynparza Gets EU Approval”
